An experimental vaccine from Merck & Co. appeared to provide broader protection against a cancer-causing virus than the company's Gardasil shot in clinical trials. Merck said the study results support its plan to submit the new vaccine, code-named V503, for U.S. regulatory approval by year's end, which could lead to market launch next year at the soonest. Some analysts expect its annual sales could exceed $1 billion. Read the full story